In this Part 2 podcast featuring Dr. Gabriel A. Bien-Willner, Medical Director of the MolDX programat Palmetto GBA, we dive into the core challenges that payers face in navigating the explosion of precision medicine tests and treatments, and specifically how the prior authorization process can be streamlined by keeping payers updated on changes in coverage policy for new genes or CDx.

Be sure to tune in to Part 1 with Dr. Bien-Willner who speaks about reshaping reimbursement policies for genetic and genomic testing.